| Literature DB >> 33271124 |
Mark Dybul1, Timothy Attoye2, Solange Baptiste3, Peter Cherutich4, François Dabis5, Steven G Deeks6, Carl Dieffenbach7, Brian Doehle2, Maureen M Goodenow8, Adam Jiang9, Dominic Kemps10, Sharon R Lewin11, Murray M Lumpkin2, Lauren Mathae12, Joseph M McCune2, Thumbi Ndung'u13, Moses Nsubuga14, Holly L Peay15, John Pottage16, Mitchell Warren17, Izukanji Sikazwe18.
Abstract
In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.Entities:
Mesh:
Year: 2020 PMID: 33271124 PMCID: PMC7773626 DOI: 10.1016/S2352-3018(20)30232-0
Source DB: PubMed Journal: Lancet HIV ISSN: 2352-3018 Impact factor: 12.767